In partnership with patient advocacy groups and industrial collaborators, we have pledged to help democratize access to physiologically relevant human models of neurodegenerative disease. The Early Access axoCells™ derived from patient-derived iPSCs are widely available to the global scientific community.
axoCells™ human iPSC-derived cortical neuron cells, media, supplements and coating kit, female donor (ax110, ApoE4/E4), ≥1.5 million cells
Features
- Derived from human iPSCs from a female donor, aged 76, with sporadic Alzheimer’s disease, ApoE4/E4
- Express the typical markers of neural stem cells (PAX6, FOXG1, SOX1 and Nestin)
- Human iPSC-derived cortical neuron cells, media, supplements and coating kit
Specifications
Number of cells: ≥1.5 million
Donor: female, aged 76
Genetics: sAD, ApoE4/E4
Price:
$3,335.00
Description
These iPSC-derived neural stem cells (NSCs) from patients with sporadic Alzheimer’s disease (sAD) provide a physiologically relevant in vitro model for investigating neurodegenerative mechanisms and advancing drug discovery.
Our NSCs are derived from human induced pluripotent stem cells (iPSCs) obtained from a female donor aged 76, clinically diagnosed with sporadic Alzheimer’s disease (sAD) and carrying the ApoE4/E4 genotype. These cells provide a physiologically relevant model for studying neurodegenerative disorders, drug discovery, and disease mechanisms in the context of Alzheimer’s pathology.
- Disease-relevant origin: derived from a sporadic Alzheimer’s disease donor (ApoE4/E4 genotype)
- Maturation potential: can be efficiently matured into cortical excitatory neurons with optimized media and supplements provided in this kit
- Cortical identity: assessed for key markers of cerebral cortical neurons, including MAP2, TBR1, CTIP2, VGLUT, and TUJ1
- Research applications: suitable for electrophysiology, neurotoxicity testing, co-culture systems, compound screenings, and neurodegeneration mechanisms
User Guides
Early Access products are derived from patient or unaffected donor iPSC lines. These individual lines may exhibit different characteristics in culture due to the unique genetic background and disease risk factors. Our User Guides provide detailed protocols, however we recommend using standard optimization techniques and monitoring cells carefully to take into account the disease phenotype and intrinsic differences in iPSC-derived cells.
If you would like to discuss the protocols, disease models, or suitable endpoint assays in more detail, please reach out to our scientific team.
Phase contrast and ICC images provide essential confirmation of cell identity, morphology, and quality. Phase contrast imaging shows the natural structure and organization of the cells, verifying healthy growth and the formation of characteristic neural rosette structures. ICC images complement this by demonstrating the expression of key neural stem cell markers such as PAX6, FOXG1, SOX1, and Nestin. These cells were assessed for key markers of cortical and striatal neurons, including MAP2, TBR1, CTIP2, VGLUT, and TUJ1, to ensure successful differentiation and functional identity. These validations provide researchers with confidence in the reproducibility and high quality of the cells, making them ideal for disease modeling, neurodevelopmental studies, and drug discovery applications.
Applications
Our axoCellsTM cortical excitatory neuron progenitors are suitable for investigating Alzheimer’s disease and for screening candidate therapies for this disease.
Healthy control lines are also available and can be used with high–content imaging, MEA, microfluidic and organ-on-chip (OOC) devices to measure structural and functional responses in neuronal models.
Quality
We maintain or exceed industry-level quality with our ISO:9001-accredited production facility, guided by our rigorous quality control procedures and decades of scientific experience.
All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Licenses & Consent
Axol has obtained all relevant licenses for reprogramming donor samples into iPSCs and differentiating these into cortical excitatory neurons for commercial use.
Patient samples used to create these neurons have been ethically sourced and consented for research and commercial use. All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Publications
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498259/
Garcia-Leon JA, Vitorica J, & Gutierrez A (2019). Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform. Future Medicinal Chemistry, 11(11), 1305–1322. doi: 10.4155/fmc-2018-0520 [PubMed] [CrossRef] [Google Scholar]
Media and Reagents
Cortical neurons: using NeurOne cortical neuron supplement, mature cerebral cortical excitatory neurons can be generated in 20 days. We also supply neural plating media, maintenance media and SureBond –XF coating as standalone items or as a kit.
Striatal neurons: using our kit of specially formulated striatal neuron media ax0333, growth factors BDNF ax139800 and GDNF ax139855, and SureBond–XF coating, mature striatal neurons can be generated in 31 days. We also supply all reagents as standalone items.
